Chimerix, Inc. (NASDAQ:CMRX) Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM reduced its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 33.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,820,792 shares of the biopharmaceutical company’s stock after selling 1,400,782 shares during the quarter. Chimerix comprises 1.4% of Monaco Asset Management SAM’s portfolio, making the stock its 8th biggest holding. Monaco Asset Management SAM’s holdings in Chimerix were worth $9,816,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. boosted its stake in shares of Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in Chimerix during the fourth quarter worth $221,000. Valeo Financial Advisors LLC raised its holdings in Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in Chimerix during the fourth quarter worth $2,626,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 over the last quarter. Insiders own 13.10% of the company’s stock.

Wall Street Analyst Weigh In

CMRX has been the subject of several research reports. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush restated a “neutral” rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $8.55 price target (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Performance

Chimerix stock opened at $8.47 on Friday. Chimerix, Inc. has a fifty-two week low of $0.75 and a fifty-two week high of $8.48. The stock has a fifty day moving average of $4.64 and a two-hundred day moving average of $2.47. The company has a market capitalization of $761.76 million, a price-to-earnings ratio of -9.01 and a beta of 0.32.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.